logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Torasemide CAS 56211-40-6

Torasemide CAS 56211-40-6

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 56211-40-6

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
56211-40-6
Appearance::
Crystalline Solid
Molecular Formula::
C16H20N4O3S
Molecular Weight::
348.42000
EINECS NO::
637-197-3
MDL NO::
MFCD00866166
CAS NO::
56211-40-6
Appearance::
Crystalline Solid
Molecular Formula::
C16H20N4O3S
Molecular Weight::
348.42000
EINECS NO::
637-197-3
MDL NO::
MFCD00866166
Torasemide CAS 56211-40-6

Product Description:

Product Name: Torasemide CAS NO: 56211-40-6

 

 

Synonyms:

N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide Torasemide;

TorseMide(DeMadex);

TorseMide API;

 

 

Chemical & Physical Properties:

Appearance: Crystalline solid

Assay :≥99.00%

Density: 1.283 g/cm3

Melting Point: 163-164℃

Refractive Index: 1.594

Storage Condition: Store in original container in a cool dark place.

Water Solubility: Soluble

 

 

Safety Information:

RTECS: UT7938000

Safety Statements: S26; S37/39

HS Code: 2935009090

Risk Statement: R36

Hazard Code: Xi

 

 

Torsemide is a pyridine-sulfonyl urea type loop diuretic.Target: OthersTorasemide is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. Torsemide significantly reduced total HF readmissions (relative risk [RR]: 0.41, 95% CI: 0.28-0.61, p < 0.0001) and HF readmissions (RR: 0.53, 95% CI: 0.33-0.84, p = 0.008) as well as CV readmissions (RR: 0.77, 95% CI: 0.60-0.98, p = 0.03) in patients with "at least 1 readmission." Torsemide caused a 14% reduction in all-cause mortality (RR: 0.86 [0.53-1.39], p = 0.54). Torsemide significantly reduces HF and CV-related hospital readmissions in systolic HF. Furthermore, torsemide is associated with a trend in reducing all-cause mortality . Torsemide has several characteristics that make it suitable for treatment of advanced heart failure including longer half-life, increased potency of diuretic action, and anti-aldosterone effects. This case report details the administration of torsemide in 3 dogs with advanced heart failure and apparent furosemide resistance .

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.